Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
ACADIA Pharmaceuticals stock has climbed 20.9% over the past month, and the broad valuation checks currently lean toward the shares looking inexpensive rather than stretched at recent prices.
The 20.9% gain over the past month suggests investors have quickly repriced ACADIA Pharmaceuticals, raising the question of how much of the recent optimism is already in the stock.
The recent positive opinion from the European Medicines Agency’s CHMP on Daybu for Rett syndrome can support higher growth expectations, while the remaining regulatory and commercial execution risks may limit how much investors are willing to pay upfront.
ACADIA Pharmaceuticals screens as relatively cheap on the broader tests, with a value score of 5 out of 6 indicating that most valuation checks point to the stock trading below what many investors might expect for its profile.
The issue now is whether ACADIA Pharmaceuticals’ recent rally has already captured the good news, or if current pricing still leaves room for further upside based on the underlying valuation signals.
The P/E ratio is a useful yardstick for ACADIA Pharmaceuticals because the company currently reports positive earnings that investors can compare to its share price. ACADIA Pharmaceuticals trades on a P/E of about 12.0x, which sits well below the broader biotech industry average of 17.8x and the peer group average of 63.7x. That is a sizeable gap, suggesting the market is applying a clear discount to ACADIA Pharmaceuticals relative to many other listed biotechs.
A more tailored fair P/E for ACADIA Pharmaceuticals, which factors in its size, business profile and risk, is estimated at around 19.0x. Against this benchmark, the current 12.0x multiple implies the stock trades at a material discount to what many investors might expect to pay for these earnings. Despite the recent CHMP recommendation for Daybu lifting sentiment, the market is still pricing ACADIA Pharmaceuticals at a lower earnings multiple than both this fair ratio and sector averages.
On the P/E multiple, ACADIA Pharmaceuticals stock currently appears undervalued relative to both its sector and a more tailored fair value benchmark.
The ACADIA Pharmaceuticals Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives for ACADIA Pharmaceuticals pick up where the valuation puzzle leaves off and spell out which combinations of future growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price. Each narrative ties its number to a concrete view on where ACADIA Pharmaceuticals’ growth, profitability and risks go next, giving you a reference point you can revisit as new information emerges on the Community page.
Community views on ACADIA Pharmaceuticals sit far apart, with some readers focused on its specialization while others fixate on concentration and policy risk.
Bull case: 8% undervalued
“For years, ACADIA was viewed through a single-product lens, that perception has slowly begun to change…”
“ACADIA remains heavily dependent on a narrow product portfolio dominated by NUPLAZID and DAYBUE, leaving the company acutely exposed to patent cliffs…”
For ACADIA Pharmaceuticals, the current market-multiple view points to an undervalued stock, with earnings being priced below both sector averages and a tailored fair P/E benchmark. That discount looks appealing only if you think the company can execute on Rett syndrome and its broader portfolio without eroding profitability or taking on risks that would justify the lower multiple.
The core question from here is whether the market is mispricing ACADIA Pharmaceuticals’ concentration and regulatory risks, or whether the current discount is a fair reflection of those uncertainties.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
